Differential effects of exogenous and autocrine growth hormone on LNCaP prostate cancer cell proliferation and survival

Journal of Cellular Biochemistry

Volumn 114, Issue 6, 2013, Pages 1322-1335

  Nakonechnaya, Alona O ^a   Jefferson, Holly S ^a   Chen, Xiaofei ^a   Shewchuk, Brian M ^a  

^a EAST CAROLINA UNIVERSITY   (United States)

Author keywords

Growth Hormone; Prostate Cancer; Signal Transduction

Indexed keywords

GROWTH HORMONE; GROWTH HORMONE RECEPTOR; JANUS KINASE 2; MESSENGER RNA; STAT5 PROTEIN;

APOPTOSIS; ARTICLE; AUTOCRINE EFFECT; CANCER CELL CULTURE; CELL PROLIFERATION; CELL SURVIVAL; CELLULAR DISTRIBUTION; CONTROLLED STUDY; ENDOPLASMIC RETICULUM; GOLGI COMPLEX; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION;

APOPTOSIS; AUTOCRINE COMMUNICATION; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; HUMAN GROWTH HORMONE; HUMANS; MALE; PROSTATIC NEOPLASMS; PROTEIN TRANSPORT; RECEPTORS, SOMATOTROPIN; SIGNAL TRANSDUCTION;

EID: 84876256620     PISSN: 07302312     EISSN: 10974644     Source Type: Journal    
DOI: 10.1002/jcb.24473     Document Type: Article

References (51)

1. Ballesteros M, Leung KC, Ross RJ, Iismaa TP, Ho KK,. 2000. Distribution and abundance of messenger ribonucleic acid for growth hormone receptor isoforms in human tissues. J Clin Endocrinol Metab 85: 2865-2871.
2. Bello D, Webber MM, Kleinman HK, Wartinger DD, Rhim JS,. 1997. Androgen responsive adult human prostatic epithelial cell lines immortalized by human papillomavirus 18. Carcinogenesis 18: 1215-1223.
3. Chan JM, Stampfer MJ, Giovannucci E, Gann PH, Ma J, Wilkinson P, Hennekens CH, Pollak M,. 1998. Plasma insulin-like growth factor-I and prostate cancer risk: A prospective study. Science 279: 563-566.
4. Chiu VK, Bivona T, Hach A, Sajous JB, Silletti J, Wiener H, Johnson RL II, Cox AD, Philips MR,. 2002. Ras signalling on the endoplasmic reticulum and the Golgi. Nat Cell Biol 4: 343-350.
5. Chopin LK, Veveris-Lowe TL, Philipps AF, Herington AC,. 2002. Co-expression of GH and GHR isoforms in prostate cancer cell lines. Growth Horm IGF Res 12: 126-136.
6. Choy E, Chiu VK, Silletti J, Feoktistov M, Morimoto T, Michaelson D, Ivanov IE, Philips MR,. 1999. Endomembrane trafficking of ras: The CAAX motif targets proteins to the ER and Golgi. Cell 98: 69-80.
7. Clemmons DR,. 2002. Roles of insulin-like growth factor-I and growth hormone in mediating insulin resistance in acromegaly. Pituitary 5: 181-183.
8. Conway-Campbell BL, Wooh JW, Brooks AJ, Gordon D, Brown RJ, Lichanska AM, Chin HS, Barton CL, Boyle GM, Parsons PG, Jans DA, Waters MJ,. 2007. Nuclear targeting of the growth hormone receptor results in dysregulation of cell proliferation and tumorigenesis. Proc Natl Acad Sci USA 104: 13331-13336.
9. Dagvadorj A, Kirken RA, Leiby B, Karras J, Nevalainen MT,. 2008. Transcription factor signal transducer and activator of transcription 5 promotes growth of human prostate cancer cells in vivo. Clin Cancer Res 14: 1317-1324.
10. Dirnhofer S, Berger C, Hermann M, Steiner G, Madersbacher S, Berger P,. 1998. Coexpression of gonadotropic hormones and their corresponding FSH- and LH/CG-receptors in the human prostate. Prostate 35: 212-220.
11. Emerald BS, Chen Y, Zhu T, Zhu Z, Lee KO, Gluckman PD, Lobie PE,. 2007. AlphaCP1 mediates stabilization of hTERT mRNA by autocrine human growth hormone. J Biol Chem 282: 680-690.
12. Evangelou AI, Winter SF, Huss WJ, Bok RA, Greenberg NM,. 2004. Steroid hormones, polypeptide growth factors, hormone refractory prostate cancer, and the neuroendocrine phenotype. J Cell Biochem 91: 671-683.
13. Flores-Morales A, Greenhalgh CJ, Norstedt G, Rico-Bautista E,. 2006. Negative regulation of growth hormone receptor signaling. Mol Endocrinol 20: 241-253.
14. Fuhrman B, Barba M, Schunemann HJ, Hurd T, Quattrin T, Cartagena R, Carruba G, Muti P,. 2005. Basal growth hormone concentrations in blood and the risk for prostate cancer: A case-control study. Prostate 64: 109-115.
15. Galbraith SM, Duchesne GM,. 1997. Androgens and prostate cancer: Biology, pathology and hormonal therapy. Eur J Cancer 33: 545-554.
16. Gatto C, McLoud SM, Kaplan JH,. 2001. Heterologous expression of Na(+)-K(+)-ATPase in insect cells: Intracellular distribution of pump subunits. Am J Physiol Cell Physiol 281: C982-C992.
17. Hansen JA, Lindberg K, Hilton DJ, Nielsen JH, Billestrup N,. 1999. Mechanism of inhibition of growth hormone receptor signaling by suppressor of cytokine signaling proteins. Mol Endocrinol 13: 1832-1843.
18. Hellgren G, Jansson JO, Carlsson LM, Carlsson B,. 1999. The growth hormone receptor associates with Jak1, Jak2, and Tyk2 in human liver. Growth Horm IGF Res 9: 212-218.
19. Hu YK, Kaplan JH,. 2000. Site-directed chemical labeling of extracellular loops in a membrane protein. The topology of the Na,K-ATPase alpha-subunit. J Biol Chem 275: 19185-19191.
20. Jelinek-Kelly S, Akiyama T, Saunier B, Tkacz JS, Herscovics A,. 1985. Characterization of a specific alpha-mannosidase involved in oligosaccharide processing in Saccharomyces cerevisiae. J Biol Chem 260: 2253-2257.
21. Jenkins PJ, Besser M,. 2001. Clinical perspective: Acromegaly and cancer: A problem. J Clin Endocrinol Metab 86: 2935-2941.
22. Kaulsay KK, Mertani HC, Tornell J, Morel G, Lee KO, Lobie PE,. 1999. Autocrine stimulation of human mammary carcinoma cell proliferation by human growth hormone. Exp Cell Res 250: 35-50.
23. Kleinberg DL, Ruan W, Yee D, Kovacs KT, Vidal S,. 2007. Insulin-like growth factor (IGF)-I controls prostate fibromuscular development: IGF-I inhibition prevents both fibromuscular and glandular development in eugonadal mice. Endocrinology 148: 1080-1088.
24. Li J, Yen C, Liaw D, Podsypanina K, Bose S, Wang SI, Puc J, Miliaresis C, Rodgers L, McCombie R, Bigner SH, Giovanella BC, Ittmann M, Tycko B, Hibshoosh H, Wigler MH, Parsons R,. 1997. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 275: 1943-1947.
25. Lincoln DT, Sinowatz F, Temmim-Baker L, Baker HI, Kolle S, Waters MJ,. 1998. Growth hormone receptor expression in the nucleus and cytoplasm of normal and neoplastic cells. Histochem Cell Biol 109: 141-159.
26. Lobie PE, Breipohl W, Aragon JG, Waters MJ,. 1990. Cellular localization of the growth hormone receptor/binding protein in the male and female reproductive systems. Endocrinology 126: 2214-2221.
27. Moutoussamy S, Kelly PA, Finidori J,. 1998. Growth-hormone-receptor and cytokine-receptor-family signaling. Eur J Biochem 255: 1-11.
28. Mukhina S, Mertani HC, Guo K, Lee KO, Gluckman PD, Lobie PE,. 2004. Phenotypic conversion of human mammary carcinoma cells by autocrine human growth hormone. Proc Natl Acad Sci USA 101: 15166-15171.
29. Ozkan EE,. 2011. Plasma and tissue insulin-like growth factor-I receptor (IGF-IR) as a prognostic marker for prostate cancer and anti-IGF-IR agents as novel therapeutic strategy for refractory cases: A review. Mol Cell Endocrinol 344: 1-24.
30. Perry JK, Emerald BS, Mertani HC, Lobie PE,. 2006. The oncogenic potential of growth hormone. Growth Horm IGF Res 16: 277-289.
31. Raccurt M, Lobie PE, Moudilou E, Garcia-Caballero T, Frappart L, Morel G, Mertani HC,. 2002. High stromal and epithelial human gh gene expression is associated with proliferative disorders of the mammary gland. J Endocrinol 175: 307-318.
32. Reiter E, Bonnet P, Sente B, Dombrowicz D, de Leval J, Closset J, Hennen G,. 1992. Growth hormone and prolactin stimulate androgen receptor, insulin-like growth factor-I (IGF-I) and IGF-I receptor levels in the prostate of immature rats. Mol Cell Endocrinol 88: 77-87.
33. Reiter E, Hennuy B, Bruyninx M, Cornet A, Klug M, McNamara M, Closset J, Hennen G,. 1999. Effects of pituitary hormones on the prostate. Prostate 38: 159-165.
34. Reiter E, Kecha O, Hennuy B, Lardinois S, Klug M, Bruyninx M, Closset J, Hennen G,. 1995. Growth hormone directly affects the function of the different lobes of the rat prostate. Endocrinology 136: 3338-3345.
35. Ruan W, Powell-Braxton L, Kopchick JJ, Kleinberg DL,. 1999. Evidence that insulin-like growth factor I and growth hormone are required for prostate gland development. Endocrinology 140: 1984-1989.
36. Slater MD, Murphy CR,. 2006. Co-expression of interleukin-6 and human growth hormone in apparently normal prostate biopsies that ultimately progress to prostate cancer using low pH, high temperature antigen retrieval. J Mol Histol 37: 37-41.
37. Sotiropoulos A, Moutoussamy S, Renaudie F, Clauss M, Kayser C, Gouilleux F, Kelly PA, Finidori J,. 1996. Differential activation of Stat3 and Stat5 by distinct regions of the growth hormone receptor. Mol Endocrinol 10: 998-1009.
38. Taichman RS, Loberg RD, Mehra R, Pienta KJ,. 2007. The evolving biology and treatment of prostate cancer. J Clin Invest 117: 2351-2361.
39. Tzelepi V, Efstathiou E, Wen S, Troncoso P, Karlou M, Pettaway CA, Pisters LL, Hoang A, Logothetis CJ, Pagliaro LC,. 2011. Persistent, biologically meaningful prostate cancer after 1 year of androgen ablation and docetaxel treatment. J Clin Oncol 29: 2574-2581.
40. Untergasser G, Rumpold H, Hermann M, Dirnhofer S, Jilg G, Berger P,. 1999. Proliferative disorders of the aging human prostate: Involvement of protein hormones and their receptors. Exp Gerontol 34: 275-287.
41. van den Eijnden MJ, Strous GJ,. 2007. Autocrine growth hormone: Effects on growth hormone receptor trafficking and signaling. Mol Endocrinol 21: 2832-2846.
42. van Garderen E, Schalken JA,. 2002. Morphogenic and tumorigenic potentials of the mammary growth hormone/growth hormone receptor system. Mol Cell Endocrinol 197: 153-165.
43. Vanderkuur JA, Butch ER, Waters SB, Pessin JE, Guan KL, Carter-Su C,. 1997. Signaling molecules involved in coupling growth hormone receptor to mitogen-activated protein kinase activation. Endocrinology 138: 4301-4307.
44. Walker SR, Nelson EA, Zou L, Chaudhury M, Signoretti S, Richardson A, Frank DA,. 2009. Reciprocal effects of STAT5 and STAT3 in breast cancer. Mol Cancer Res 7: 966-976.
45. Wang Z, Luque RM, Kineman RD, Ray VH, Christov KT, Lantvit DD, Shirai T, Hedayat S, Unterman TG, Bosland MC, Prins GS, Swanson SM,. 2008. Disruption of growth hormone signaling retards prostate carcinogenesis in the Probasin/TAg rat. Endocrinology 149: 1366-1376.
46. Wang Z, Prins GS, Coschigano KT, Kopchick JJ, Green JE, Ray VH, Hedayat S, Christov KT, Unterman TG, Swanson SM,. 2005. Disruption of growth hormone signaling retards early stages of prostate carcinogenesis in the C3(1)/T antigen mouse. Endocrinology 146: 5188-5196.
47. Weiss-Messer E, Merom O, Adi A, Karry R, Bidosee M, Ber R, Kaploun A, Stein A, Barkey RJ,. 2004. Growth hormone (GH) receptors in prostate cancer: Gene expression in human tissues and cell lines and characterization, GH signaling and androgen receptor regulation in LNCaP cells. Mol Cell Endocrinol 220: 109-123.
48. Wilson SS, Crawford ED,. 2006. Controversies of androgen ablation therapy for metastatic prostate cancer. Curr Pharm Des 12: 799-805.
49. Yang XP, Ghoreschi K, Steward-Tharp SM, Rodriguez-Canales J, Zhu J, Grainger JR, Hirahara K, Sun HW, Wei L, Vahedi G, Kanno Y, O'Shea JJ, Laurence A,. 2011. Opposing regulation of the locus encoding IL-17 through direct, reciprocal actions of STAT3 and STAT5. Nat Immunol 12: 247-254.
50. Zhang X, Zhu T, Chen Y, Mertani HC, Lee KO, Lobie PE,. 2003. Human growth hormone-regulated HOXA1 is a human mammary epithelial oncogene. J Biol Chem 278: 7580-7590.
51. Zhu T, Ling L, Lobie PE,. 2002. Identification of a JAK2-independent pathway regulating growth hormone (GH)-stimulated p44/42 mitogen-activated protein kinase activity. GH activation of Ral and phospholipase D is Src-dependent. J Biol Chem 277: 4592-4603.